Vesalio Receives Peripheral FDA 510k Clearance and Additional CE Approval
Vesalio reports it has obtained an FDA 510k clearance and its 4th CE approval. The FDA 510k indication is for the removal of thrombi in peripheral blood vessels.
Initiates Virtual Training and Announces Pass Effect Rate Publication
Vesalio announces it has executed additional exclusive distribution agreements in Europe, Latin America, Asia, and the Middle East. With these new partnerships, the NeVa™ Thrombectomy System has gained market coverage in 53 countries.
Vesalio Obtains Additional CE Approval for New Products, NeVa™ Clinical Data Published
Vesalio announces it has obtained its second CE Approval spanning multiple new NeVa™ product designs and technology. The new generation NeVa devices expand on the Drop Zone™ and Smart Marker™ technologies.
Vesalio™ Secures $5 Million Investment Capital Funding
Vesalio announces it has recently raised $5 million in funding. The capital will support the continued global expansion of the NeVa™ Neurothrombectomy System, finance key clinical studies and launch new product introductions.
Expansion of International Distributor Network and Stroke Congress Exhibition Presence
Vesalio announces it has executed multiple exclusive distribution agreements in Europe, Latin America, Asia and the Middle East and now has market coverage in 39 countries for the NeVa™ Neuro-thrombectomy System.
Vesalio Initiates Full Commercial Launch of NeVa at the 10th Anniversary of ESMINT
Vesalio announces it has initiated the full commercial European launch of its NeVa neurothrombectomy platform at the 10th annual congress of the European Society of Minimally Invasive Neurological Therapy.
Vesalio Reports Expansion of Commercial Distribution, Additional Published Data on the NeVa™ System
Vesalio announces it has executed multiple exclusive distribution agreements in Europe and now has market coverage in 25 countries for the NeVa Neurothrombectomy System.
Positive Results in Early NeVa™ Human Thrombectomy Procedures
Vesalio announces it has completed European enrollment of the first twenty-five human cases in a post-market registry of the proprietary NeVa™ neurothrombectomy platform for the treatment of stroke.
Vesalio Announces NeVa™ Stroke Treatment Product CE Mark Certification
Vesalio announces the CE Mark certification of its first product line, the proprietary NeVa™ neurothrombectomy platform for the treatment of stroke.
